A. David Marais

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Raúl D. Santos, Dirk Blom et al. · The Lancet · 2010 · 906 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Marina Cuchel, Emma A. Meagher, Hendrik du Toit Theron et al. · The Lancet · 2012 · 740 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +12

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

Amanda J. Hooper, A. David Marais, Donald Moshen Tanyanyiwa et al. · Atherosclerosis · 2006 · 365 citations

Life Sciences, Genetics, Molecular Genetics +9

Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

Frederick J. Raal, Gillian J. Pilcher, Vanessa R. Panz et al. · Circulation · 2011 · 364 citations · Full text

Medicine, Cardiology, Genetics +17

Statin Therapy Reduces the Mycobacterium tuberculosis Burden in Human Macrophages and in Mice by Enhancing Autophagy and Phagosome Maturation

Suraj P. Parihar, Reto Guler, Rethabile Khutlang et al. · The Journal of Infectious Diseases · 2013 · 309 citations · Full text

Life Sciences, Immunology, Pharmacology +17